https://www.selleckchem.com/pr....oducts/itacitinib-in
. First-line durvalumab plus platinum-etoposide showed sustained overall survival improvement versus platinum-etoposide but the addition of tremelimumab to durvalumab plus platinum-etoposide did not significantly improve outcomes versus platinum-etoposide. These results support the use of durvalumab plus platinum-etoposide as a new standard of care for the first-line treatment of ES-SCLC. AstraZeneca. AstraZeneca.Acute heart failure (HF) management is a complex and often involves a delicate balance of both cardiac and renal
Like
Comment
Share
